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Mutations in Ribonucleic Acid Binding Protein
Gene Cause Familial Dilated Cardiomyopathy
Katharine M. Brauch, MS,* Margaret L. Karst, BA,* Kathleen J. Herron, BA,*
Mariza de Andrade, PHD,§ Patricia A. Pellikka, MD,† Richard J. Rodeheffer, MD,†
Virginia V. Michels, MD, Timothy M. Olson, MD*†‡
Rochester, Minnesota
Objectives We sought to identify a novel gene for dilated cardiomyopathy (DCM).
Background DCM is a heritable, genetically heterogeneous disorder that remains idiopathic in the majority of patients. Familial
cases provide an opportunity to discover unsuspected molecular bases of DCM, enabling pre-clinical risk detection.
Methods Two large families with autosomal-dominant DCM were studied. Genome-wide linkage analysis was used to
identify a disease locus, followed by fine mapping and positional candidate gene sequencing. Mutation scanning
was then performed in 278 unrelated subjects with idiopathic DCM, prospectively identified at the Mayo Clinic.
Results Overlapping loci for DCM were independently mapped to chromosome 10q25-q26. Deoxyribonucleic acid se-
quencing of affected individuals in each family revealed distinct heterozygous missense mutations in exon 9 of
RBM20, encoding ribonucleic acid (RNA) binding motif protein 20. Comprehensive coding sequence analyses
identified missense mutations clustered within this same exon in 6 additional DCM families. Mutations segre-
gated with DCM (peak composite logarithm of the odds score 11.49), were absent in 480 control samples,
and altered residues within a highly conserved arginine/serine (RS)-rich region. Expression of RBM20 messenger
RNA was confirmed in human heart tissue.
Conclusions Our findings establish RBM20 as a DCM gene and reveal a mutation hotspot in the RS domain. RBM20 is prefer-
entially expressed in the heart and encodes motifs prototypical of spliceosome proteins that regulate alternative
pre-messenger RNA splicing, thus implicating a functionally distinct gene in human cardiomyopathy. RBM20
mutations are associated with young age at diagnosis, end-stage heart failure, and high mortality. (J Am Coll
Cardiol 2009;54:930–41) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.038p
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prevention of heart failure has been a major public health
ocus, founded on knowledge of pathogenic mechanisms
nd modifiable risk factors for hypertension and coronary
rtery disease (1). Heart failure remains an idiopathic
ondition, however, in 50% of adults (2) and 66% of
hildren (3) referred to cardiologists, and end-stage idio-
athic dilated cardiomyopathy (DCM) is the most common
ndication for cardiac transplantation (4,5). Indeed, onset of
eart failure symptoms in DCM typically portends ad-
anced myocardial disease and risk for sudden death (6)
fter years to decades of clinically silent but insidiously
rom the *Cardiovascular Genetics Laboratory, †Division of Cardiovascular Diseases,
epartment of Internal Medicine, ‡Division of Pediatric Cardiology, Department of
ediatric and Adolescent Medicine, §Department of Health Sciences Research, and
he Department of Medical Genetics, College of Medicine, Mayo Clinic, Rochester,
innesota. This work was supported by the National Heart, Lung, and Blood
nstitute, National Institutes of Health (R01 HL071225), and the Marriott Program
or Heart Disease Research.T
Manuscript received February 18, 2009; revised manuscript received April 7, 2009,
ccepted May 10, 2009.rogressive myopathy. Even in children, this inherent delay
n diagnosis and treatment of DCM accounts for 10-year
ransplantation-free survival of only 42% (3). Improved
rediction, treatment, and prevention of DCM will require
iscovery of pre-clinical biomarkers, better tools for risk-
tratification, and the molecular and cellular basis of disease
o enable mechanism-based therapies (1).
See page 942
Recognition of DCM as a familial disorder in 20% to
8% of cases (7–11) has provided a rationale for routine
creening echocardiography in at-risk relatives to detect
re-symptomatic disease (12). Moreover, it has been the
mpetus for human genetics investigations to uncover the
olecular basis of DCM (13,14). Since 1993, pathogenic
utations in over 20 genes encoding cytoskeletal, contrac-
ile, nuclear membrane, calcium-regulating, and ion channel
roteins have been identified in patients with DCM (15).
he majority of studies are hypothesis-based, targeting
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September 1, 2009:930–41 Mutations in RBM20 Cause Familial DCMandidate genes like cardiac actin (16) that encode proteins
ith established function in the heart. By contrast, unan-
icipated DCM genes and insights into disease pathobiology
ave emerged from rare families suitable for whole genome
apping studies (17–20). Here, we used genetic linkage
nalysis in 2 large families with autosomal-dominant DCM
o map a disease locus, leading to discovery of a mutation
otspot within a ribonucleic acid (RNA)-binding protein
ene associated with high morbidity and mortality.
ethods
tudy subjects. Patients with DCM evaluated at the Mayo
linic in the years 1987 to 1992 and 1999 to 2008 and their
elatives were recruited, and medical records were reviewed.
e enrolled 280 unrelated probands; familial DCM was
onfirmed in 24% (DCM documented in 1 first degree
elative) and suspected in 27% (on the basis of history
lone). Family history of sudden death was present in 18%.
he 8 families described in the current study were white and
f northern European ancestry by self-reporting. An ethni-
ally matched group of 480 control subjects with normal
chocardiograms was randomly selected from a community-
ased cohort (21). Subjects provided written informed
onsent under research protocols approved by the Mayo
linic Institutional Review Board.
Echocardiograms in relatives were performed for clinical
ndications or under the auspices of the research study.
iagnostic criteria for DCM were: lack of an identifiable
ause for disease, left ventricular diastolic and/or systolic
imensions 95th percentile indexed for body surface area
22), and left ventricular ejection fraction 50%. Subjects
ith normal echocardiograms were classified as “unaf-
ected,” and those with equivocal or insufficient data were
lassified as “uncertain.” Genomic deoxyribonucleic acid
DNA) was isolated from peripheral-blood white cells
Puregene Blood Kit, Gentra/QIAGEN, Valencia, Califor-
ia) or from paraffin-embedded tissue (QIAamp DNA
FPE Tissue Kit, QIAGEN).
inkage analysis and fine mapping. Genome-wide link-
ge analysis was performed with the ABI PRISM Linkage
apping Set MD10, version 2.5 (Applied Biosystems,
oster City, California), consisting of polymerase chain
eaction (PCR) primer pairs for 400 short tandem repeat
arkers. After PCR amplification of DNA samples, frag-
ents were resolved on an ABI PRISM 3130xl, and
enotypes were scored with GeneMapper Software (Ap-
lied Biosystems). Two-point and multipoint linkage anal-
ses were performed using the FASTLINK program and
pecification of the following variables: a phenocopy rate of
.001, equal marker allele frequencies, and dichotomous
iability classes (“affected” and “unaffected”). For mutations,
frequency of 0.001 was specified. Logarithm of the odds
LOD) scores were determined for affected subjects only
nd for 80% and 100% penetrance models at recombination
requencies of 0.0 to 0.4. fFine locus mapping was per-
ormed with microsatellite mark-
rs on physical maps, accessible
n the website of the National
enter for Biotechnology Infor-
ation (NCBI) (23). Genotyp-
ng was accomplished by PCR
mplification of DNA radiola-
eled with [alpha32P] deoxycyti-
ine triphosphate, resolution of
lleles by polyacrylamide-gel
lectrophoresis, and visualization
y autoradiography. Scored ge-
otypes were assembled as hap-
otypes to define the critical re-
ion.
utation detection and haplo-
ype analysis. Expression pro-
les of candidate genes, derived
rom Affymetrix GeneChip array
ata for 12 normal human tissues
accession GDS424) or 61 nor-
al mouse tissues (accession
DS592), were assessed by
earching the Gene Expression
mnibus (GEO) link on the
CBI website (24). The genomic structure of RBM20 was
ased on predicted reference messenger ribonucleic acid
mRNA) sequence (accession NM_001134363.1), retrieved
rom NCBI. Primer pairs were designed for genomic DNA
CR-amplification of the coding regions of the 14 pre-
icted exons (Online Table 1), with Oligo Primer Analysis
oftware, version 6.71 (Molecular Biology Insights, Cas-
ade, Colorado). For sequencing, amplified products were
reated with ExoSAP-IT (USB Corp., Cleveland, Ohio)
nd sequenced by the dye-terminator method with use of an
BI PRISM 3730xl DNA Analyzer (Applied Biosystems).
he DNA sequences were viewed and analyzed with Se-
uencher, version 4.5 DNA analysis software (Gene Codes
orp., Ann Arbor, Michigan). The reference mRNA and
erived protein sequence (accession NP_001127835.1) were
sed for annotation of identified mutations.
Denaturing high-performance liquid chromatography
DHPLC) heteroduplex analysis (WAVE DHPLC Sys-
em, Transgenomic, Omaha, Nebraska) was used to screen
or sequence variants in our DCM cohort and control
amples. Ideal buffer gradients and column melting temper-
tures were determined with Transgenomic Navigator soft-
are version 1.7.0 Build 25 and subsequent optimization
Online Table 1). Chromatographic elution profiles of
mplified fragments were compared against the wild-type
omoduplex pattern; samples yielding anomalous traces
ere selected for sequencing. To test for a common founder
mong families with the same RBM20 mutation, haplotypes
Abbreviations
and Acronyms
cDNA  complementary
deoxyribonucleic acid
DCM  dilated
cardiomyopathy
DHPLC  denaturing high-
performance liquid
chromatography
DNA  deoxyribonucleic
acid
GEO  Gene Expression
Omnibus
ICD  implantable
cardioverter-defibrillator
LOD  logarithm of the
odds
mRNA  messenger
ribonucleic acid
NCBI  National Center for
Biotechnology Information
PCR  polymerase chain
reaction
RNA  ribonucleic acid
RS  arginine/serineor mutant alleles were constructed from an intragenic
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Mutations in RBM20 Cause Familial DCM September 1, 2009:930–41etranucleotide-repeat sequence and single nucleotide poly-
orphisms, identified by sequencing family members.
ardiac mRNA expression and protein structure analysis.
otal RNA was extracted from frozen human heart tis-
ue (RNeasy Fibrous Tissue Midi Kit, QIAGEN), and 1.0
g was reverse transcribed with an oligo(dT) primer to
roduce complementary deoxyribonucleic acid (cDNA)
rom mRNA (SMART RACE cDNA Amplification Kit,
lontech, Mountain View, California). Primers cDNA-F
CCTACCCCAGATCATCCAAAATGC) and cDNA-R
AACAAACACTTTGCAGTCAGTTATACA) were
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Figure 1 Pedigrees of Index Families With Hereditary Dilated C
Pedigree structures for kindreds DC-12 (A) and DC-35 (B) are shown. Square  m
unknown; parallel diagonal lines  suspected dilated cardiomyopathy (DCM) on th
death indicated. The gene for ribonucleic acid binding motif protein 20 (RBM20) is
some 10 are listed in order from centromere to q-telomere, with map locations ac
megabases and centimorgans. The haplotypes for these markers are shown in co
ated haplotypes are boxed. Question marks indicate genotypes that could not be
of portions of the disease haplotype in some affected subjects (DC-12: III.2, III.3,
to be defined by the minimal region of overlap. The RBM20 missense mutations (R
bols indicate wild-type sequence. *Proband. ALZ  Alzheimer’s disease; CA  can
infarction; MS  multiple sclerosis; MVA  motor vehicle accident; Pn  pneumoesigned to PCR amplify and sequence 5=-RACE-Ready RDNA, spanning the RBM20 region containing the iden-
ified mutations. A subsequent nested reaction with primers
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onserved structural domains. Conservation of amino acids
ltered by RBM20 missense mutations was investigated by
ligning our translated RBM20 cDNA sequence with
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henotype of index families. Clinical data and DNA
amples were collected from 2 large families in which a
linically aggressive form of DCM segregated as an
utosomal-dominant trait (Fig. 1, Table 1). Kindred DC-12
as recruited for the study in 1991, when an unaffected
amily member sought medical genetics consultation. The
atriarch (Fig. 1A: I.1) was of Scottish ancestry and died
uddenly at age 39 years. Ten family members developed
ocumented DCM, 2 as young children (mean age at
iagnosis: 30.0 years). Two underwent cardiac transplanta-
ion as young adults, and all but 3 have died of their disease
mean age at death: 37.7 years). Kindred DC-35 was
ecruited in 2005, after a diagnostic screening echocardio-
ram in the proband (Fig. 1B) (III.17) whose father died
uddenly at age 29 years. The family was of Norwegian
ncestry and comprised 12 relatives with documented DCM
mean age at diagnosis: 41.3 years) and 5 others with DCM
nd/or sudden death by history alone. Seven family mem-
ers with confirmed or suspected DCM died at a mean age
f 45.7 years. Five living relatives with DCM had received
mplantable cardioverter-defibrillators (ICDs).
CM locus mapping. Genome-wide linkage analyses,
ollowed by regional high-density genotyping on chromo-
ome 10, identified a peak 2-point LOD score of 3.55 at
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Figure 1 Continuedarker D10S1269 in DC-12 and 4.55 at marker D10S221 Rn DC-35. Linkage to other regions of the genome with
-point LOD scores 1.0 was excluded by multipoint
nd/or haplotype analyses with additional markers (data not
hown). Fine mapping in DC-12 identified a disease-
ssociated haplotype on chromosome 10q25.1-q26.2 (Fig.
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ubjects, assuming 100% mutation penetrance, and 2.67 for
ffected subjects only). A recombination event within this
nterval occurred in a 43-year-old woman with a normal
chocardiogram (III.14). The critical region narrowed to 4.6
b, assuming she did not inherit the disease-associated
utation. Fine mapping in DC-35 identified an overlap-
ing disease-associated haplotype (Fig. 1B) spanning 22.8
b (peak multipoint LOD score 4.89 for all subjects,
ssuming 100% mutation penetrance, and 3.58 for affected
ubjects only). The haplotypes were different for each
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CM gene.
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Phenotypic and Genetic Data for Families With DCMTable 1 Phenotypic and Genetic Data for Families With DCM
Pedigree
(Country of
Origin)
Age at
Diagnosis
(yrs)
Age at
Evaluation (yrs)
(Indication)
LVID
(mm)
LVEF
(%) ECG, Arrhythmia
Other Diagnostic
Testing Treatment Outcome Pathology Diagnosis
RBM20
Mutation Status
DC-12
(Scotland)
II.5 — 58 (F) 55/31 68 Normal None Alive 58 yrs Unaffected Normal
II.9 53 53 (R) 64*/53* 39 LVH, PVC Death 58 yrs DCM P638L
II.10 44 45 (S) Severe LVE* LVSD AF, PVC D, F CHF, death
45 yrs
Autopsy: congestive
myopathy,
fibrosis, myocyte
hypertrophy, no
CAD
DCM P638L (inferred)
III.2 28 28 (S) SD 28 yrs Autopsy: EFE,
congestive
myopathy, no
CAD
DCM P638L
III.3 37 37 (F) 62*/57* 15 LAD, VT Neg. angio D, B Death 41 yrs Autopsy: mild
fibrosis
DCM P638L
III.5 30 (R) 40/24 64 Normal Death 38 yrs Autopsy: normal
LV and cardiac
mass, no CAD
Uncertain (suspected
arrhythmia)
Normal
III.8 36 (F) 43/30 51 Normal None Alive 39 yrs Unaffected Normal
III.9 30’s 36 (S) LBBB Transplant 36 yrs Death 36 yrs DCM P638L
III.11 33 33 (F) 72*/62* 26 LVH, IVCD D, C Alive 42 yrs DCM P638L
III.13 29 29 (S) SD 29 yrs Autopsy: CM, mild
fibrosis, no CAD
DCM P638L
III.14 43 (F) 51/36 50 Normal None Alive 46 yrs Unaffected Normal
III.15 24 25 (F) 88*/79* 15 LVH, IVCD Transplant 26 yrs Death 27 yrs DCM P638L
III.16 14 14 (F)¡
22
57*/41*¡
57*/41*
48¡
45
Short PR, SVT D, So Alive 24 yrs DCM P638L
IV.1 3 3 (F)¡
12
44*/30*¡
62*/40*
50¡
64
Short PR, LVH D, L Alive 12 yrs DCM P638L
DC-35
(Norway)
III.1 55 55 (F) 47/39* 46 PAC Neg. stress imaging Alive 58 yrs DCM R634Q
III.6 45 45 (S)¡
55
70*/¡
60*/50*
10¡
30
LAE, IVCD, ST-T Neg. angio D, Cv, L, Sp, W, ICD
(EF, FH)
Alive 55 yrs DCM R634Q
III.7 60 (F) 44/29 60 Normal None Alive 62 yrs Unaffected Normal
III.8 60 (F) 39/29 60 None Alive 60 yrs Unaffected Normal
III.9 52 (F) Normal 65 Normal None Alive 56 yrs Unaffected Normal
III.10 51 (HTN) 44/28 67 None Alive 52 yrs Unaffected Normal
III.11 55 55 (S) 72*/63* 20 Short PR, IVCD,
ST-T, VT
D, Cv, L, ICD (EF,
FH, VT)
Alive 55 yrs DCM R634Q
III.12 47 47 (A) Death 47 yrs Autopsy: CM and
LV dilation
DCM
Continued on next page
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ContinuedTable 1 Continued
Pedigree
(Country of
Origin)
Age at
Diagnosis
(yrs)
Age at
Evaluation (yrs)
(Indication)
LVID
(mm)
LVEF
(%) ECG, Arrhythmia
Other Diagnostic
Testing Treatment Outcome Pathology Diagnosis
RBM20
Mutation Status
III.14 46 52 (F) 63*/51* 30 ICD (EF, FH) Alive 52 yrs DCM R634Q
III.15 51 (F) 54/27 55 None Alive 51 yrs Unaffected Normal
III.17 48 48 (F) 61*/44* 45 IVCD, ST-T, VT Neg. angio M, L, ICD (FH) Alive 49 yrs DCM R634Q
IV.1 50 50 (S) 64*/55* 20 LAD, LAE, ST-T Neg. angio Cv, L Alive 52 yrs DCM R634Q
IV.2 37 37 (S) Severe LVE* 15 LAE, LAD Neg. angio,
CK 102 U/l
D, E, W CHF, death
37 yrs
Biopsy: myocyte
hypertrophy,
mild fibrosis
DCM
IV.3 44 (F) 56*/36 65 Normal None Alive 48 yrs Uncertain Normal
IV.4 44 (F) 51/32 52 Normal None Alive 46 yrs Unaffected Normal
IV.5 40 40 (F) 56*/43* 40 Normal Neg. stress
imaging;
CK 70 U/l,
cTnI 0.3 ng/ml
M, L Alive 44 yrs DCM R634Q
IV.6 24 (F) 54*/35 58 Normal Neg. stress imaging None Alive 27 yrs Uncertain R634Q
IV.7 23 (F) 39/27 65 None Alive 23 yrs Unaffected Normal
IV.8 18 18 (F) 61*/51* 37 IVCD, LVH Neg. angio Cv, L, ICD (FH, EF) Alive 19 yrs DCM
IV.9 30 30 (R) 63*/45* 42 Normal Alive 30 yrs DCM R634Q
IV.10 24 24 (R) 59/46* 45 LVH Alive 24 yrs DCM R634Q
DC-50
(Germany)
II.3 49 52 (S)¡
60
68*/62*¡
71*/65*
17¡
15
LVH, ST-T, AF, VT,
VF
Neg. angio,
CK 43 U/l,
cTnI 0.5 ng/ml
D, F, P, C, A, W,
ICD (Sy, FH)
CHF, death
60 yrs
Autopsy: sev. CM,
mild fibrosis
DCM P638L
II.5 29 29 (S) ST-T, VT, VF CK 29 U/l D, P, PC CHF, death
29 yrs
DCM P638L (inferred)
III.3 25 25 (R)¡
42
55*/45*¡
51/—
33¡
40
LVH D, Cv, L Alive 42 yrs DCM P638L
III.4 29 29 (R)¡
44
45/35¡
52/38*
40¡
49
ST-T Cv, E Alive 44 yrs DCM P638L
III.5 15 15 (S) 75*/68* 18 LVH, ST-T, VT D, L, W, N, Mx CHF, SD 18
yrs
Biopsy: myocyte
hypertrophy,
mild fibrosis
DCM
III.6 29 (R) 51/28 70 Normal None Alive 46 yrs Unaffected Normal
III.7 27 (R) 50/32 60 Normal None Alive 36 yrs Unaffected Normal
III.8 21 27 (R)¡
37
54*/40*¡
56*/46*
51¡
35
Short PR, SVT Cv, L Alive 38 yrs DCM P638L
IV.1 17 17 (S) 51/40* 40 LVH, SVT M, E Alive 22 yrs DCM P638L
DC-46
(Germany)
IV.1 26 18 (F)¡
26
53/36¡
56*/46*
58¡
30
ST-T cTnT 0.03 ng/ml Cv, L, ICD (EF, FH) Alive 27 yrs DCM R636S
Continued on next page 935
JACC
Vol.54,No.10,2009
Brauch
et
al.
Septem
ber1,2009:930–41
M
utations
in
RBM
20
Cause
Fam
ilialDCM
ContinuedTable 1 Continued
Pedigree
(Country of
Origin)
Age at
Diagnosis
(yrs)
Age at
Evaluation (yrs)
(Indication)
LVID
(mm)
LVEF
(%) ECG, Arrhythmia
Other Diagnostic
Testing Treatment Outcome Pathology Diagnosis
RBM20
Mutation Status
DC-49
(Germany)
II.2 40 40 (S)¡
45
71*/64*¡
65*/52*
10¡
20
LVH, ST-T, IVCD,
VT
D, M, L, Sp, F, W,
Mx, ICD (CA)
Alive 45 yrs DCM R636H
II.3 39 39 (F)¡
44
63*/49*¡
52/42*
43¡
45
VT Neg. angio Cv, Rm, Cn Alive 44 yrs DCM R636H
DC-27
(Norway)
II.6 70 80 (S) 63*/— 25 SB, AF D, Cv, L, F, W CHF, death
85 yrs
DCM R636S
III.2 64 (F) 55*/40* 50 IRBBB Cv Alive 64 yrs Uncertain R636S
III.3 59 None SD 59 yrs Autopsy: CM, LVE,
CAD but no acute
MI, fibrosis
DCM R636S (inferred)
III.5 55 59 (F) 59*/44* 44 1° AVB, RBBB,
VT
Neg. angio Cv Alive 60 yrs DCM R636S
III.8 50 (F) 45/— 60 Normal None Alive 55 yrs Unaffected Normal
III.10 39 (F) 54/38* 55 None Alive 47 yrs Uncertain R636S
IV.1 35 35 (S) 68*/55* 38 LVH, ST-T Neg. angio Cv, L Alive 36 yrs DCM R636S
IV.5 27 36 (S) 72*/65* 23 LAD, IVCD, ST-T Neg. angio Cv, Ln Alive 37 yrs Biopsy: myocyte
hypertrophy,
mod. fibrosis
DCM R636S
IV.7 28 (R) 50/33 66 Normal None Alive 31 yrs Unaffected Normal
IV.9 15 (F) 52*/34 57 Normal None Alive 18 yrs Uncertain R636S
DC-09
(Norway)
III.2 57 57 (R)¡
68
58*/46*¡
59*/49*
35¡
34
Short PR, PVC D, E, F, A Alive 68 yrs DCM R636S
III.4 Neg. angio Alive 68 yrs DCM (by history) R636S
IV.2 17 17 (S) 68*/60* 22 LVH, ST-T D, H, N, F, W CHF, SD 18
yrs
DCM
IV.3 27 (R) 50/32 60 Normal None Alive 38 yrs Unaffected R636S
IV.4 24 (R) 53/33 61 Normal None Alive 36 yrs Unaffected Normal
IV.6 19 20 (S) Transplant 20 yrs Alive 43 yrs DCM R636S
DC-22
(England)
II.2 44 45 (S) 53*/44* 25 ST-T, VT Neg. angio D, F, A, Cv, Ln, ICD
(EF, FH)
CHF, alive
54 yrs
DCM S637G
II.3 27 27 (S) Transplant 32 yrs Alive 49 yrs DCM S637G
Continued on next page
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September 1, 2009:930–41 Mutations in RBM20 Cause Familial DCMhe basis of its genomic location and expression pattern.
mong 12 human tissues, RBM20 is most highly expressed
n the heart, with transcript abundance 4-fold greater in
ardiac than in skeletal muscle according to GEO array
ata. Moreover, it is 1 of only 19 genes with a mean
xpression in the heart 8-fold higher than the combined
ean expression in 11 other tissues. Similarly, among 61
urine tissues it is most highly expressed in heart (5-fold
keletal muscle). Sequencing of the 14 exons of RBM20
dentified a distinct heterozygous missense mutation in exon
in each family, resulting in a P638L substitution in
C-12 and a R634Q substitution in DC-35 (Figs. 1 and
A). Mutations cosegregated with the disease phenotype
nd were absent in unaffected family members and 480
thnically matched control subjects.
To determine whether RBM20 mutations were present in
ther cases of DCM, we screened the 14 coding exons in
ur remaining cohort of 278 subjects with DHPLC. Three
nique heterozygous missense mutations—R636S, R636H,
nd S637G—were identified in 6 other families, all clus-
ered within exon 9 (Figs. 2 and 3A). Among the 8 families
ith RBM20 mutations, 2 had an identical mutation
esulting in P638L substitution, and 3 had an identical
utation resulting in R636S substitution. Haplotype anal-
sis (Online Table 3) excluded a common ancestral founder
or the P638L substitution. Although the disease-associated
aplotypes were the same in the 3 families with an R636S
ubstitution, the majority of individual alleles comprising
he haplotype are the most common variants within a white
uropean population. Consequently, a founder effect could
ot be conclusively established. Mutations were absent in
ontrol samples and cosegregated with DCM in the 7
amilies where DNA samples were available from 2 or more
ffected subjects. Combined peak 2-point LOD scores for
utations versus DCM in the 4 largest families (DC-12,
C-35, DC-27, DC-50) ranged from 8.02 (affected sub-
ects only) to 11.49 (all subjects, assuming 100% mutation
enetrance).
ardiac mRNA expression and protein structure
nalysis. RBM20 comprises, on the basis of the predicted
eference cDNA (mRNA), 14 exons (Fig. 3B). Portions of
xons 2 and 14 and all of exons 3 through 13 were verified
n a single open reading frame cDNA derived from
ligo(dT)-primed heart RNA (Fig. 3B). This confirmed
hat these exons are transcribed and spliced into mRNA in
he heart, including exon 9, which contained the cluster of
dentified RBM20 mutations. A Conserved Domain Data-
ase search of the translated reference RBM20 cDNA
ndicated homology to an RNA Recognition Motif 1
uperfamily domain spanning exons 6 and 7 (e-value 
.005) and a U1 zinc finger domain (e-value  2e4)
panning exons 13 and 14. Additionally, exon 9 encodes an
rginine/serine (RS)-rich domain, which is disrupted by the
identified unique missense mutations. Each resultant
mino acid substitution alters a residue in RBM20 con-served among diverse species (Fig. 3C).Co T
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Mutations in RBM20 Cause Familial DCM September 1, 2009:930–41enotype-phenotype correlation. RBM20 mutations
ere associated with clinically aggressive DCM. Collec-
ively, the 39 subjects in our 8 families with a mutation
nd confirmed DCM were diagnosed 9 years earlier than
comparable series of patients with sporadic and familial
CM who underwent family screening (mean age at
iagnosis 35.9 vs. 45.2 years) (7). Death occurred in 11
mean age 45.2 years) and was deemed sudden in 3; 4
nderwent cardiac transplantation (mean age 28.5 years);
nd 8 underwent ICD insertion. Subjects who enrolled in
ur study, however, did not fully represent the malignant
ature of their familial disease as revealed by their
edigrees. Among the 32 additional relatives with sus-
ected DCM by family history, for whom medical
ecords were unavailable and/or mutation status could not
e determined, 13 died suddenly (mean age 32.7 years), 3
nderwent cardiac transplantation, and 3 had ICD inser-
ion. There were no consistent electrocardiographic fea-
ures in subjects with an RBM20 mutation; 9 had
entricular tachycardia. Variable degrees of myocyte hy-
ertrophy and interstitial fibrosis were observed on his-
opathological analysis. Most enrolled subjects with ac-
DC-27
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Figure 2 Pedigrees of Additional Families With RBM20 Mutatio
Diamonds  2 or more family members of both sexes; parentheses  inferred RBessible follow-up data had advanced disease and ixhibited minimal improvement or further deterioration
n medical treatment, although drug therapy was highly
ariable. Correlation between RBM20 mutations and
henotype was not without exception, however. There
ere 5 female subjects who inherited a mutation but did
ot fulfill diagnostic criteria for DCM: 1 subject in
C-35 (age 24 years) and 3 subjects in DC-27 (ages 15,
9, and 64 years) had left ventricular enlargement with
ormal ejection fraction; 1 subject in DC-9 (age 27 years)
ad a normal echocardiogram. No overt noncardiac
henotypes were evident among subjects with RBM20
utations.
iscussion
olecular basis of disease. The majority of known
CM genes encode cytoskeletal or contractile proteins of
ardiac myocytes, with direct roles in the generation
nd/or transmission of contractile force through protein–
rotein interactions (14). An expanded understanding of
he pathobiology of DCM has emerged from identifica-
ion of mutations that perturb myocardial function via
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etic etiologies for DCM reveal a fundamental defect in
xcitation-contraction coupling and the heart’s capacity
o perform under physiologic and stress conditions.
otable exceptions to this paradigm have been revealed
hrough discovery of unsuspected DCM genes, like
MNA and EYA4, in large families suitable for linkage
nalysis. LMNA encodes lamin A/C, a ubiquitously
xpressed nuclear membrane protein. By unknown mech-
nisms, mutations in LMNA cause DCM and conduction
ystem disease (17) or a spectrum of noncardiac disorders.
YA4 encodes a transcriptional coactivator, which inter-
1        2   3     4 5    6      7    8
500 bp
RRM-1 R
ATG
Heart cDNA
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Zebrafish
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G C C G CG G T C T C
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R634Q
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R636S
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 
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Figure 3 RBM20 Mutations Identified in Families With Dilated
(A) Genomic deoxyribonucleic acid (DNA) mutation scans with denaturing high-perf
pared with the control wild-type profile (gray), in exon 9 of RBM20 in 8 dilated car
were absent in 480 control samples. Below the heteroduplex profiles, DNA sequen
mutation and its resultant amino acid substitution are based on predicted referen
indicated below each chromatogram. Mutation c.1906 CA, R636S was shared b
genomic structure of RBM20, consisting of 14 exons, is depicted to scale. Exons
acid (RNA) recognition motif 1 (RRM-1, in purple), arginine/serine-rich region (RS-ri
and stop (TGA) codons are located in exons 1 and 14, respectively. A polyadenyla
genomic structure, cDNA amplification and sequencing confirmed transcription of m
alignment. The cDNA transcript contains the complete RS domain and identified R
tein sequences that flank the amino acid substitutions is shown. The RS domain s
low. Residues conserved between human RBM20 and another species are indicat
identified RBM20 missense mutations (residues 634, 636, 637, and 638, indicat
NP_001127835.1 for human, XP_508032 for chimpanzee, XP_544017 for dog, X
chicken, XP_683222 for zebrafish, and CAG01297 for pufferfish.cts with DNA-binding transcription factors. Mutations mn EYA4 are predicted to alter cochlear and cardiac gene
xpression, causing a syndrome of DCM and sensori-
eural hearing loss (20). RBM20, here identified as a
ene for familial DCM, suggests perturbation of post-
ranscriptional pre-mRNA processing as a distinct mo-
ecular basis for the disorder.
RBM20 encodes RNA binding motif protein 20, with
prototypical RNA-recognition motif followed by an RS
omain (27). These structural features are characteristic
f a family of RNA-binding SR proteins that assemble in
he spliceosome, a large multiprotein complex that or-
hestrates constitutive and alternative splicing of pre-
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xons, conferring vast diversity to the proteome (29).
eritable diseases are frequently attributable to cis-acting
utations, which disrupt normal splicing of the gene in
hich the mutation occurs. However, trans-acting muta-
ions within spliceosome protein genes have been iden-
ified in only 3 human disorders—spinal muscular atro-
hy, retinitis pigmentosa, and Prader-Willi syndrome
28). Such mutations have the potential to impair normal
plicing of multiple genes, as recently demonstrated by
xon microarray analysis in a mouse model of spinal
uscular atrophy (30). The specific function of RNA
inding motif protein 20 in the human heart and the
ownstream effects of the identified RBM20 mutations
hat cause DCM remain unknown. However, a patho-
enic link between genetic disruption of alternative
plicing-regulating SR proteins of the spliceosome and
CM has now been established in mouse models (31).
linical implications. Since the first DCM-associated
ene was identified by linkage analysis over 15 years ago
32,33), clinical application of research findings has proved
hallenging due to the marked genetic heterogeneity of
CM. Although routine genetic testing might be practical
n certain heritable cardiac disorders (34), no single gene or
utation for DCM has emerged as common (15). Targeted
enetic testing might be practical, however, in clinically
efined subgroups. For example, mutations in LMNA
nd SCN5A have been associated with a cardiac syndrome
f DCM, impaired automaticity and conduction, and
trial fibrillation (17–19). By use of genome-wide linkage
nalysis, the present study further expands the spectrum
f DCM genes. Remarkably, the 5 unique RBM20
utations identified in 8 families are clustered within a
ingle exon that encodes an RS-rich domain. In our
ohort, this mutation hotspot accounted for 3% (8 of
80) of all DCM cases, 5% (8 of 151) of confirmed or
uspected familial cases, and 13% (7 of 54) of cases with
history of sudden death.
Our study highlights the importance of family screen-
ng to detect pre-symptomatic DCM (7,12). Indeed, 68%
43 of 63) of the subjects in our 8 families were
symptomatic and first diagnosed with DCM on the basis
f a screening echocardiogram. Despite the lack of
ymptoms, the RBM20 mutations we identified were
ighly penetrant, and only 5 of 44 individuals with a
utation did not fulfill diagnostic criteria for DCM. In
act, 4 of these 5 subjects had left ventricular dilation, a
nown precursor to overt DCM (7,10). However, pen-
trance of familial DCM is age dependent, and the
ajority of subjects who enrolled in our study were
dults. Discovery of the genetic basis for DCM in these
amilies now enables a pre-clinical diagnosis in at-risk
hildren and young adults. Given the malignant nature of
BM20 mutations, this knowledge would justify closer
linical follow up, meticulous attention to coexistent
odifiable risk factors, and earlier institution of therapiesroven to alter the natural history of heart failure (35)
nd decrease the risk of sudden death (6).
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